BR112019001035A2 - beenato de rotigotina, e método de preparação e uso do mesmo - Google Patents
beenato de rotigotina, e método de preparação e uso do mesmoInfo
- Publication number
- BR112019001035A2 BR112019001035A2 BR112019001035-1A BR112019001035A BR112019001035A2 BR 112019001035 A2 BR112019001035 A2 BR 112019001035A2 BR 112019001035 A BR112019001035 A BR 112019001035A BR 112019001035 A2 BR112019001035 A2 BR 112019001035A2
- Authority
- BR
- Brazil
- Prior art keywords
- rotigotine
- beenate
- behenate
- preparation
- manufacture
- Prior art date
Links
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title abstract 7
- 229960003179 rotigotine Drugs 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 3
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 abstract 3
- 229940116224 behenate Drugs 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 230000036470 plasma concentration Effects 0.000 abstract 2
- 102000015554 Dopamine receptor Human genes 0.000 abstract 1
- 108050004812 Dopamine receptor Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
- C07D333/10—Thiophene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/090803 WO2018014277A1 (zh) | 2016-07-21 | 2016-07-21 | 罗替戈汀山嵛酸酯及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019001035A2 true BR112019001035A2 (pt) | 2019-04-30 |
Family
ID=60992805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019001035-1A BR112019001035A2 (pt) | 2016-07-21 | 2016-07-21 | beenato de rotigotina, e método de preparação e uso do mesmo |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10669249B2 (https=) |
| EP (1) | EP3489227B1 (https=) |
| JP (1) | JP6751208B2 (https=) |
| KR (1) | KR20190031314A (https=) |
| CN (1) | CN109415335B (https=) |
| AU (1) | AU2016415408B2 (https=) |
| BR (1) | BR112019001035A2 (https=) |
| CA (1) | CA3030043C (https=) |
| ES (1) | ES2855976T3 (https=) |
| MY (1) | MY195897A (https=) |
| PH (1) | PH12018550212A1 (https=) |
| PL (1) | PL3489227T3 (https=) |
| RU (1) | RU2717542C9 (https=) |
| SG (1) | SG11201811543XA (https=) |
| WO (1) | WO2018014277A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2717542C9 (ru) * | 2016-07-21 | 2020-08-12 | Шаньдун Луе Фармасьютикал Ко., Лтд. | Ротиготина бегенат, его способ получения и применение |
| CN108341798B (zh) * | 2017-01-23 | 2021-05-25 | 沈阳药科大学 | 罗替戈汀衍生物及其制备和应用 |
| CN114423746A (zh) * | 2019-09-30 | 2022-04-29 | 山东绿叶制药有限公司 | 化合物及其制备方法和用途 |
| JP7621009B2 (ja) * | 2020-10-27 | 2025-01-24 | ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 | テトラヒドロナフタレン系化合物、その医薬組成物及びその使用 |
| WO2024208226A1 (zh) * | 2023-04-04 | 2024-10-10 | 广州市恒诺康医药科技有限公司 | 四氢萘类化合物、其药物组合物及其用途 |
| CN119504742B (zh) * | 2024-11-18 | 2025-10-28 | 陕西师范大学 | 一种娃儿藤碱和安托芬的全合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2239196T3 (es) * | 2002-12-02 | 2005-09-16 | Schwarz Pharma Ag | Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson. |
| DE10361259A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
| KR101481643B1 (ko) | 2010-11-25 | 2015-01-12 | 산동 루예 파마슈티칼 컴파니 리미티드 | 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물 |
| WO2013168033A1 (en) * | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| US9956201B2 (en) * | 2014-07-21 | 2018-05-01 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms |
| WO2016014242A1 (en) * | 2014-07-21 | 2016-01-28 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods |
| RU2717542C9 (ru) * | 2016-07-21 | 2020-08-12 | Шаньдун Луе Фармасьютикал Ко., Лтд. | Ротиготина бегенат, его способ получения и применение |
-
2016
- 2016-07-21 RU RU2018146096A patent/RU2717542C9/ru active
- 2016-07-21 SG SG11201811543XA patent/SG11201811543XA/en unknown
- 2016-07-21 PL PL16909205T patent/PL3489227T3/pl unknown
- 2016-07-21 US US16/309,807 patent/US10669249B2/en active Active
- 2016-07-21 KR KR1020197005257A patent/KR20190031314A/ko not_active Abandoned
- 2016-07-21 AU AU2016415408A patent/AU2016415408B2/en active Active
- 2016-07-21 ES ES16909205T patent/ES2855976T3/es active Active
- 2016-07-21 CN CN201680087177.7A patent/CN109415335B/zh active Active
- 2016-07-21 JP JP2019524492A patent/JP6751208B2/ja active Active
- 2016-07-21 CA CA3030043A patent/CA3030043C/en not_active Expired - Fee Related
- 2016-07-21 BR BR112019001035-1A patent/BR112019001035A2/pt not_active IP Right Cessation
- 2016-07-21 MY MYPI2018002909A patent/MY195897A/en unknown
- 2016-07-21 WO PCT/CN2016/090803 patent/WO2018014277A1/zh not_active Ceased
- 2016-07-21 EP EP16909205.3A patent/EP3489227B1/en active Active
-
2018
- 2018-12-26 PH PH12018550212A patent/PH12018550212A1/en unknown
-
2020
- 2020-04-27 US US16/860,037 patent/US11111227B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3489227T3 (pl) | 2021-05-04 |
| JP2019523297A (ja) | 2019-08-22 |
| MY195897A (en) | 2023-02-27 |
| US20200255396A1 (en) | 2020-08-13 |
| RU2717542C1 (ru) | 2020-03-24 |
| PH12018550212A1 (en) | 2019-10-28 |
| AU2016415408B2 (en) | 2019-04-11 |
| EP3489227B1 (en) | 2020-10-21 |
| US10669249B2 (en) | 2020-06-02 |
| CN109415335A (zh) | 2019-03-01 |
| AU2016415408A1 (en) | 2019-01-17 |
| CA3030043C (en) | 2021-01-19 |
| JP6751208B2 (ja) | 2020-09-02 |
| SG11201811543XA (en) | 2019-02-27 |
| WO2018014277A1 (zh) | 2018-01-25 |
| CN109415335B (zh) | 2020-06-05 |
| US20190330177A1 (en) | 2019-10-31 |
| EP3489227A4 (en) | 2020-01-22 |
| ES2855976T3 (es) | 2021-09-27 |
| EP3489227A1 (en) | 2019-05-29 |
| US11111227B2 (en) | 2021-09-07 |
| RU2717542C9 (ru) | 2020-08-12 |
| CA3030043A1 (en) | 2018-01-25 |
| KR20190031314A (ko) | 2019-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019001035A2 (pt) | beenato de rotigotina, e método de preparação e uso do mesmo | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| JO3475B1 (ar) | ناهضات مستقبل سوماتوستاتين نوع فرعي 4 (sstr4) جديدة | |
| BR112016010383A2 (pt) | compostos de pyy seletivos e usos dos mesmos | |
| DOP2015000245A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| MX2023006541A (es) | Formulaciones de dosis fija. | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| GT201300243A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso | |
| MX2016007067A (es) | Microcapsulas lipidicas que comprenden de preferencia un retinoide y composicion que las contiene, su procedimiento de preparacion y su uso en dermatologia. | |
| UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
| ECSP12012326A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| DOP2015000170A (es) | Compuestos químicos | |
| CL2015003357A1 (es) | Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos | |
| MX389600B (es) | Nueva composición terapéutica que contiene ingrediente activo de apomorfinas. | |
| BR112017002214A2 (pt) | composto de fórmula (i), composição farmacêutica e usos de um composto | |
| DOP2016000253A (es) | Nuevos compuestos | |
| BR112015008297A2 (pt) | antagonistas de mglu2/3 para o tratamento de distúrbios autistas | |
| EA029499B9 (ru) | Ингибиторы rorc2 и способы их применения | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| BR112015030431A2 (pt) | formulação de liberação modificada | |
| CL2012003006A1 (es) | Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2680 DE 17-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |